glp-1 small molecule agonist Emerging Trends in the Development of Receptor Agonists A potent novel small molecule

And its working

Cortagen acts on the brain and nervous system, with potential relevance to neuroimmune conditions like MS

fat breakdown) while preserving lean muscle mass, helping endurance athletes maintain muscle hypertrophy, body composition and energy levels

Local / Intralesional Injection Injection directly at or near the site of injury used in some animal studies for tendon and joint applications

Biochemistry 1993

Protocol 4: degenerative disc disease and facet arthritis (advanced) Goal: Slow degenerative processes and support tissue quality in chronic spinal degeneration Peptides: BPC-157 : 500mcg twice daily ongoing GHK-Cu : 2mg daily for tissue regeneration KPV : 300mcg daily for anti-inflammatory effects Optional : TB-500 2mg weekly for systemic support Duration: Extended protocols, potentially cycling on and off Why this works: Degenerative conditions require ongoing support rather than acute treatment